Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Post by MrMugsyon May 11, 2023 7:04am
180 Views
Post# 35442543

This should be your first clue ...

This should be your first clue ...
Jonathan Ross Goodman Elected 57,085,576 95.03% 2,985,127 4.97%
James C. Gale Elected 59,496,395 99.04% 574,308 0.96%
Samira Sakhia Elected 59,788,314 99.53% 282,389 0.47%


You should take this as your first clue ... approval ratings are high.

Remember when Gale's rating was in the 80%-90% range?  Not anymore, cuz Meir is gone.

The shares are controlled by those who are happy with the company's development.

So, no matter how much you whine or cry about it - it's business-as-usual at GUD.

Not an opinion - it's fact.  Facts like this make some people very angry.

Absolutely nothing you can do about it.

Therefore, you invest because you agree with them - OR - you exit because it isn't for you.




Absolutely a waste of time arguing against it - now that's my opinion only.

: )




<< Previous
Bullboard Posts
Next >>